For example, upregulation of IL-12r or CTLA-4 (Figure 6) in both the HTB-1 and SiHa models may suggest a combination with an IL-12 or CTLA-4 modulating agent which may enhance the observed anti-tumor response. The gene discussed is IL12RB1; the disease is neoplasm.